featured
Pathologic and Molecular Responses to Neoadjuvant Trastuzumab and/or Lapatinib in HER2-Positive Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nature Communications
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pathologic and Molecular Responses to Neoadjuvant Trastuzumab and/or Lapatinib From a Phase II Randomized Trial in HER2-Positive Breast Cancer (TRIO-US B07)
Nat Commun 2020 Nov 17;[EPub Ahead of Print], SA Hurvitz, JL Caswell-Jin, KL McNamara, JJ Zoeller, GR Bean, R Dichmann, A Perez, R Patel, L Zehngebot, H Allen, L Bosserman, B DiCarlo, A Kennedy, A Giuliano, C Calfa, D Molthrop, A Mani, HW Chen, J Dering, B Adams, E Kotler, MF Press, JS Brugge, C Curtis, DJ SlamonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.